Effect of Lumacaftor/Ivacaftor on glucose metabolism and insulin secretion in Phe508del homozygous cystic fibrosis patients
Journal of Cystic Fibrosis Dec 23, 2017
Thomassen JC, et al. - The changes in glucose metabolism and insulin secretion were assessed, herein, subsequent to the receipt of Lumacaftor/Ivacaftor in patients with cystic fibrosis (CF) (Phe508del/Phe508del). No consistent impact of Lumacaftor/Ivacaftor on glucose tolerance and insulin secretion was demonstrated in this population.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
